TH-302 is designed to release cytotoxic bromo-isophosphoramide (Br-IPM) moiety in hypoxic microenvironment. Therefore, this drug preferentially attacks the hypoxic region in cancer where other standard anti-cancer treatment such as chemotherapy and radiation therapy are ineffective. Here, we monitored the change in tumor hypoxia and perfusion in response to TH-302 treatment by EPR oximetry and DCE MRI using two pancreatic ductal adenocarcinoma xenograft models. The result showed improved oxygenation only in treatment sensitive MIA Paca-2 tumors without modulating tumor blood perfusion, suggesting that intratumor pO2 is a useful biomarker to evaluate treatment response to TH-302.
This abstract and the presentation materials are available to members only; a login is required.